Real-World data sought on myeloma drug combo

This study will review medical records of 300 UK patients with newly diagnosed multiple myeloma who cannot have a stem cell transplant and are treated with a three-drug combination (daratumumab, lenalidomide, and dexamethasone). The goal is to see how well this therapy works in everyday practice outside of clinical trials. Researchers will measure response rates, survival, and how often doses need adjustment.